ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 223 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,700 | -66.4% | 13,156 | -58.6% | 0.01% | -64.3% |
| Q2 2023 | $213,405 | -31.8% | 31,804 | -10.3% | 0.01% | -26.3% |
| Q1 2023 | $313,059 | +80.7% | 35,454 | +56.3% | 0.02% | +111.1% |
| Q4 2022 | $173,260 | -76.3% | 22,678 | -77.9% | 0.01% | -65.4% |
| Q3 2022 | $732,000 | -3.9% | 102,816 | +9.1% | 0.03% | +18.2% |
| Q2 2022 | $762,000 | -62.2% | 94,225 | -35.1% | 0.02% | -62.1% |
| Q1 2022 | $2,015,000 | +811.8% | 145,182 | +2137.4% | 0.06% | +866.7% |
| Q3 2021 | $221,000 | -31.2% | 6,489 | -17.3% | 0.01% | -40.0% |
| Q2 2021 | $321,000 | -80.5% | 7,850 | -80.8% | 0.01% | -76.7% |
| Q1 2021 | $1,646,000 | +445.0% | 40,893 | +699.9% | 0.04% | +437.5% |
| Q4 2020 | $302,000 | +357.6% | 5,112 | +274.0% | 0.01% | +166.7% |
| Q3 2020 | $66,000 | +1550.0% | 1,367 | +855.9% | 0.00% | – |
| Q3 2019 | $4,000 | – | 143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |